Becton Dickinson — Nov 7, 2024 release

GAAP revenue growth of 8.9% to 9.4% and currency-neutral adjusted revenue growth of 8.8% to 9.3% include the newly acquired APM business. The company's organic revenue growth guidance of 4.0% to 4.5% includes absorbing an impact about 125 basis points from an expected decline in revenues in China and Bioscience and Pharma market dynamics. Fiscal 2025 Guidance as of November 7, 2024 GAAP Revenues ~$21.9 to $22.1 billion GAAP Revenue Growth 8.9% to 9.4% Adjusted Revenue Growth (FXN) 8.8% to 9.3% Organic Revenue Growth (FXN) 4.0% to 4.5% Adjusted Diluted EPS $14.25 to $14.60 Adjusted Diluted EPS Growth ~8.5% to 11.0% BD's outlook for fiscal 2025 reflects numerous assumptions about many factors that could affect its business, based on the information management has reviewed as of this date. Management will discuss its outlook and several of its assumptions on its fourth fiscal quarter earnings call. The company's expected adjusted diluted EPS for fiscal 2025 excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, spin-related costs, and certain tax matters. BD does not attempt to provide reconciliations of forward-looking adjusted diluted non-GAAP EPS guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict